Selected article for: "appropriate testing and mortality rate"

Author: Triggle, Chris R.; Bansal, Devendra; Farag, Elmoubasher Abu Baker Abd; Ding, Hong; Sultan, Ali A.
Title: COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions
  • Cord-id: ucipq8uk
  • Document date: 2020_5_13
  • ID: ucipq8uk
    Snippet: Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first emerged in December 2019 in Wuhan, Hubei province, China. Since then, the virus has rapidly spread to many countries. While the outbreak in China appears to be in decline, the disease has spread across the world, with a daily increase in the number of confirmed cases and infection-related deaths. Here, we highlight (i) the lessons that have been learnt so
    Document: Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first emerged in December 2019 in Wuhan, Hubei province, China. Since then, the virus has rapidly spread to many countries. While the outbreak in China appears to be in decline, the disease has spread across the world, with a daily increase in the number of confirmed cases and infection-related deaths. Here, we highlight (i) the lessons that have been learnt so far and how they will benefit reducing the impact of COVID-19 disease and (ii) an update on the status of drug treatment and vaccine development to prevent COVID-19 and potential future related pandemics. Although the mortality rate is clearly higher than for influenza, the rate does seem to vary from country to country, possibly reflecting differences in how rapidly local health authorities respond to isolate and effectively care for the affected population. Drugs are urgently needed for both prophylaxis and the treatment of severely ill patients; however, no proven effective therapies for SARS-CoV-2 currently exist. A number of drugs that have been approved for other diseases are being tested for the treatment of COVID-19 patients, but there is an absence of data from appropriately designed clinical trials showing that these drugs, either alone or in combination, will prove effective. There is also a global urgency to develop a vaccine against COVID-19, but development and appropriate testing will take at least a year before such a vaccine will be globally available. This review summarizes the lessons learnt so far from the COVID-19 pandemic, examines the evidence regarding the drugs that are being tested for the treatment of COVID19, and describes the progress made in efforts to develop an effective vaccine.

    Search related documents:
    Co phrase search for related documents
    • acute pneumonia and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute pneumonia and lopinavir ritonavir combination: 1
    • acute pneumonia and low number: 1, 2
    • acute pneumonia and lung detect: 1, 2, 3, 4
    • acute pneumonia and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
    • acute pneumonia and lung pathology: 1, 2, 3, 4, 5, 6, 7
    • local community and low number: 1, 2, 3
    • local community and lung infection: 1
    • lopinavir ritonavir and low number: 1
    • lopinavir ritonavir and lung infection: 1, 2, 3, 4, 5, 6, 7, 8
    • lopinavir ritonavir and lung pathology: 1
    • lopinavir ritonavir and lupus rheumatoid arthritis: 1, 2
    • lopinavir ritonavir and macrolide antibiotic: 1, 2
    • lopinavir ritonavir and macular retinopathy: 1
    • low number and lung detect: 1
    • low number and lung infection: 1
    • low number and lupus rheumatoid arthritis: 1, 2
    • lung infection and lupus rheumatoid arthritis: 1
    • lung infection and lymph immune cell: 1